CARY, N.C., May 19 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), formerly known as Critical Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced the departure of Scott B. Townsend, Esq., General Counsel and Executive Vice President of Legal Affairs, effective June 5, 2009. The Company has already begun a search for a successor.
"I would like to thank Scott for his contributions to the Company during his many years of service, and in particular since the closing of last year's merger," said Craig A. Collard, Cornerstone's President and Chief Executive Officer. "Scott's knowledge of Critical Therapeutics' pre-merger business was especially helpful as we integrated the operations of the combined company and filed our first post-merger Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as the Proxy Statement for our first post-merger annual stockholders' meeting, which will be held on May 28, 2009. Scott recognized that, at this juncture in our development, we need a general counsel who is located full-time at our North Carolina headquarters, but told us that, for family reasons, he is currently unable to relocate from Massachusetts. Thus, we mutually agreed that it would be prudent to make this management change at this time. We appreciate Scott agreeing to remain with us through our annual stockholders' meeting."
Cornerstone currently retains Raleigh, North Carolina-based Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. as its external legal counsel.
About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respi
|SOURCE Cornerstone Therapeutics Inc.|
Copyright©2009 PR Newswire.
All rights reserved